ArticleJournal of the anus, rectum and colon2019

A Trial Protocol of Biweekly TAS-102 and Bevacizumab as Third-Line Chemotherapy for Advanced/Recurrent Colorectal Cancer: A Phase II Multicenter Clinical Trial (The TAS-CC4 Study).

Yoichiro Yoshida et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.